Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA™) is an antibody-drug
conjugate being developed for the treatment of B cell lymphomas by ADC Therapeutics SA …

Antibody‐drug conjugates (ADCs) have emerged as a promising class of biologics since the
first approval of Gemtuzumab ozogamicin in 2000. Compared to small molecule drugs …

Introduction The rationally designed pyrrolobenzodiazepine (PBD) dimers emerged around
ten years ago as a new class of drug component for antibody-drug conjugates (ADC). They …

Summary CD276/B7-H3 represents a promising target for cancer therapy based on
widespread overexpression in both cancer cells and tumor-associated stroma. In previous …

Antibody-based therapeutics have experienced a rapid growth in recent years and are now
utilized in various modalities spanning from conventional antibodies, antibody-drug …

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies
treatment, designed to provide superior efficacy and specific targeting of tumor cells …

Antibody-drug conjugates (ADCs) are targeted therapies with the expectation of broadened
therapeutic window due to tumor-specific drug delivery. Recent approvals, including ADCs …